ATE251448T1 - Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen - Google Patents

Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen

Info

Publication number
ATE251448T1
ATE251448T1 AT99968164T AT99968164T ATE251448T1 AT E251448 T1 ATE251448 T1 AT E251448T1 AT 99968164 T AT99968164 T AT 99968164T AT 99968164 T AT99968164 T AT 99968164T AT E251448 T1 ATE251448 T1 AT E251448T1
Authority
AT
Austria
Prior art keywords
oil suspensions
polyol
proteins
delayed release
active agent
Prior art date
Application number
AT99968164T
Other languages
English (en)
Inventor
Merrill Seymour Goldenberg
Daxian Shan
Alice C Beekman
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/221,181 external-priority patent/US6245740B1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE251448T1 publication Critical patent/ATE251448T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
AT99968164T 1998-12-23 1999-12-20 Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen ATE251448T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/221,181 US6245740B1 (en) 1998-12-23 1998-12-23 Polyol:oil suspensions for the sustained release of proteins
US44820599A 1999-11-23 1999-11-23
PCT/US1999/030527 WO2000038652A1 (en) 1998-12-23 1999-12-20 Polyol/oil suspensions for the sustained release of proteins

Publications (1)

Publication Number Publication Date
ATE251448T1 true ATE251448T1 (de) 2003-10-15

Family

ID=26915566

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968164T ATE251448T1 (de) 1998-12-23 1999-12-20 Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen

Country Status (16)

Country Link
EP (1) EP1140018B1 (de)
JP (1) JP2002533378A (de)
KR (1) KR100491815B1 (de)
CN (1) CN1158068C (de)
AT (1) ATE251448T1 (de)
AU (1) AU769610B2 (de)
CA (1) CA2355618C (de)
DE (1) DE69911993T2 (de)
DK (1) DK1140018T3 (de)
ES (1) ES2204187T3 (de)
HU (1) HUP0104756A3 (de)
IL (2) IL143706A0 (de)
PT (1) PT1140018E (de)
SI (1) SI1140018T1 (de)
TW (1) TWI221777B (de)
WO (1) WO2000038652A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
JP4361710B2 (ja) 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
IL155730A0 (en) 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
PT1397155E (pt) 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP2020990B1 (de) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
KR101434706B1 (ko) 2007-02-16 2014-08-26 아스카 세이야쿠 가부시키가이샤 미립자 유성 현탁액을 포함하는 의약 조성물
US20080227805A1 (en) 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
EP3907237A1 (de) 2012-12-20 2021-11-10 Amgen Inc. Apj-rezeptor-agonisten und verwendungen davon
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
US10941182B2 (en) 2014-06-10 2021-03-09 Amgen Inc. Apelin polypeptides
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
WO2022215899A1 (ko) * 2021-04-08 2022-10-13 주식회사 티온랩테라퓨틱스 서방성 지질 전구 제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3482657D1 (de) * 1983-11-21 1990-08-09 Univ Minnesota Gepuffertes polyol-hormones gemisch zur verwendung bei chronischer parenteraler hormonverabreichung.
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
US5114929A (en) * 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions

Also Published As

Publication number Publication date
DE69911993D1 (de) 2003-11-13
SI1140018T1 (en) 2003-12-31
WO2000038652A1 (en) 2000-07-06
TWI221777B (en) 2004-10-11
EP1140018A1 (de) 2001-10-10
HUP0104756A3 (en) 2006-04-28
AU769610B2 (en) 2004-01-29
PT1140018E (pt) 2004-02-27
DK1140018T3 (da) 2004-02-02
JP2002533378A (ja) 2002-10-08
DE69911993T2 (de) 2004-05-19
CA2355618A1 (en) 2000-07-06
CN1158068C (zh) 2004-07-21
KR20010099864A (ko) 2001-11-09
IL143706A (en) 2008-04-13
KR100491815B1 (ko) 2005-05-27
CN1335765A (zh) 2002-02-13
IL143706A0 (en) 2002-04-21
AU2483800A (en) 2000-07-31
CA2355618C (en) 2007-03-13
EP1140018B1 (de) 2003-10-08
ES2204187T3 (es) 2004-04-16
HUP0104756A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
DE69911993D1 (de) Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
ATE309007T1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
BR9810495A (pt) Composição farmacêutica
EP1100522A4 (de) Verabreichung aktiver wirkstoffe über die lunge
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
NZ527157A (en) Compositions for delivering bisphosphonates
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
EE04450B1 (et) Farmatseutilised kompositsioonid kahe või enama toimeainega aerosoolidele
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
AU2845599A (en) Pharmaceutical compositions and their use
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
BR9811094A (pt) Agente terapêutico para tumores linfáticos
DE69819145D1 (de) Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
EA200400041A1 (ru) Сочетание действующих ингредиентов, используемое в качестве вызывающего привыкание фармакологического средства или для интоксикационной терапии
ES2171086T3 (es) Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica.
PT1235579E (pt) Composicoes farmaceuticas contendo trimegestona
EP0995430A3 (de) Verwendung von Wirkstoffen, gewählt aus der Gruppe der 1,2-Diacylglycerole, zur Stärkung der Barrierefunktion der Haut
BR9810433A (pt) Composições anti-helmìnticas
BR0001661A (pt) Composições pesticidas
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140018

Country of ref document: EP

REN Ceased due to non-payment of the annual fee